Cost of arthropathic diseases therapy with biologicals disease modifying drugs (bDMARs): a 5-year cost analysis at national level
AbstractThis study analysed the changes in the reimbursed cost, prices and utilization of biological medicines for a 5-year time horizon, encompassing three major arthropathic diagnoses, rheumatoid arthritis (RA), psoriatic arthropathies (PsA) and ankylosing spondylitis (AS), from the point of view...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-12-01
|
| Series: | Biotechnology & Biotechnological Equipment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/13102818.2022.2131468 |
| _version_ | 1797974139183562752 |
|---|---|
| author | Konstantin Tachkov Vladimira Boyadzhieva Ivan Manev Nikolay Stoilov Zornitsa Mitkova Konstantin Mitov Guenka Petrova |
| author_facet | Konstantin Tachkov Vladimira Boyadzhieva Ivan Manev Nikolay Stoilov Zornitsa Mitkova Konstantin Mitov Guenka Petrova |
| author_sort | Konstantin Tachkov |
| collection | DOAJ |
| description | AbstractThis study analysed the changes in the reimbursed cost, prices and utilization of biological medicines for a 5-year time horizon, encompassing three major arthropathic diagnoses, rheumatoid arthritis (RA), psoriatic arthropathies (PsA) and ankylosing spondylitis (AS), from the point of view of the third-party payer in Bulgaria. National; population based; macroeconomic; top-down budget analysis was performed based on official data about the number of inhabitants, reimbursed diagnoses and medicines, reimbursed cost, treated patients, and prices of medicines. The utilization of medicines was calculated in DDD per 1000/inh/day. There was an increase of 41% in the number of patients treated with biological medicines. The reimbursement cost of biologicals increased by 21%; however, the per-patient reimbursement costs per diagnosis fell by 40% due to price decreases. Out of 21 reimbursed diagnoses, we saw a significant difference in prevalence (612 SD in 2016 to 1216 SD in 2020; p < 0.05). RA accounted for 2736 patients in 2016, increasing by 131% to 4662 patients in 2020; AS with 1933 patients in 2016 reached 3196 patients by 2020, and PsA with 1128 patients ranked third with a 75% increase. The cost of therapy of RA was the highest, accounting for appr. 15 mill Euro in 2016. The utilization decreased only for 2 INNs (infliximab and rituximab). All INNs experienced a nearly two-fold increase in their utilization: from 0.5244 to 0.9252 DDD/1000inh/day. The cost analysis shows an important place of biologicals for arthropathic diseases therapy; introduction of biosimilars leads to prices and cost decreases. |
| first_indexed | 2024-04-11T04:15:20Z |
| format | Article |
| id | doaj.art-919c894e4c5f4369a47fa1a89fde7652 |
| institution | Directory Open Access Journal |
| issn | 1310-2818 1314-3530 |
| language | English |
| last_indexed | 2024-04-11T04:15:20Z |
| publishDate | 2022-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Biotechnology & Biotechnological Equipment |
| spelling | doaj.art-919c894e4c5f4369a47fa1a89fde76522022-12-31T18:03:16ZengTaylor & Francis GroupBiotechnology & Biotechnological Equipment1310-28181314-35302022-12-0136182883710.1080/13102818.2022.2131468Cost of arthropathic diseases therapy with biologicals disease modifying drugs (bDMARs): a 5-year cost analysis at national levelKonstantin Tachkov0Vladimira Boyadzhieva1Ivan Manev2Nikolay Stoilov3Zornitsa Mitkova4Konstantin Mitov5Guenka Petrova6Department of Organisation and Economy of Pharmacy, Faculty of Pharmacy, Medical University of Sofia, Sofia, BulgariaDepartment of Rheumatology, Faculty of Medicine, Medical University of Sofia, Sofia, BulgariaDepartment of Organisation and Economy of Pharmacy, Faculty of Pharmacy, Medical University of Sofia, Sofia, BulgariaDepartment of Rheumatology, Faculty of Medicine, Medical University of Sofia, Sofia, BulgariaDepartment of Organisation and Economy of Pharmacy, Faculty of Pharmacy, Medical University of Sofia, Sofia, BulgariaDepartment of Organisation and Economy of Pharmacy, Faculty of Pharmacy, Medical University of Sofia, Sofia, BulgariaDepartment of Organisation and Economy of Pharmacy, Faculty of Pharmacy, Medical University of Sofia, Sofia, BulgariaAbstractThis study analysed the changes in the reimbursed cost, prices and utilization of biological medicines for a 5-year time horizon, encompassing three major arthropathic diagnoses, rheumatoid arthritis (RA), psoriatic arthropathies (PsA) and ankylosing spondylitis (AS), from the point of view of the third-party payer in Bulgaria. National; population based; macroeconomic; top-down budget analysis was performed based on official data about the number of inhabitants, reimbursed diagnoses and medicines, reimbursed cost, treated patients, and prices of medicines. The utilization of medicines was calculated in DDD per 1000/inh/day. There was an increase of 41% in the number of patients treated with biological medicines. The reimbursement cost of biologicals increased by 21%; however, the per-patient reimbursement costs per diagnosis fell by 40% due to price decreases. Out of 21 reimbursed diagnoses, we saw a significant difference in prevalence (612 SD in 2016 to 1216 SD in 2020; p < 0.05). RA accounted for 2736 patients in 2016, increasing by 131% to 4662 patients in 2020; AS with 1933 patients in 2016 reached 3196 patients by 2020, and PsA with 1128 patients ranked third with a 75% increase. The cost of therapy of RA was the highest, accounting for appr. 15 mill Euro in 2016. The utilization decreased only for 2 INNs (infliximab and rituximab). All INNs experienced a nearly two-fold increase in their utilization: from 0.5244 to 0.9252 DDD/1000inh/day. The cost analysis shows an important place of biologicals for arthropathic diseases therapy; introduction of biosimilars leads to prices and cost decreases.https://www.tandfonline.com/doi/10.1080/13102818.2022.2131468Biological medicinesarthropathic diseasescost of therapydiseases modifying antirheumatic medicines |
| spellingShingle | Konstantin Tachkov Vladimira Boyadzhieva Ivan Manev Nikolay Stoilov Zornitsa Mitkova Konstantin Mitov Guenka Petrova Cost of arthropathic diseases therapy with biologicals disease modifying drugs (bDMARs): a 5-year cost analysis at national level Biotechnology & Biotechnological Equipment Biological medicines arthropathic diseases cost of therapy diseases modifying antirheumatic medicines |
| title | Cost of arthropathic diseases therapy with biologicals disease modifying drugs (bDMARs): a 5-year cost analysis at national level |
| title_full | Cost of arthropathic diseases therapy with biologicals disease modifying drugs (bDMARs): a 5-year cost analysis at national level |
| title_fullStr | Cost of arthropathic diseases therapy with biologicals disease modifying drugs (bDMARs): a 5-year cost analysis at national level |
| title_full_unstemmed | Cost of arthropathic diseases therapy with biologicals disease modifying drugs (bDMARs): a 5-year cost analysis at national level |
| title_short | Cost of arthropathic diseases therapy with biologicals disease modifying drugs (bDMARs): a 5-year cost analysis at national level |
| title_sort | cost of arthropathic diseases therapy with biologicals disease modifying drugs bdmars a 5 year cost analysis at national level |
| topic | Biological medicines arthropathic diseases cost of therapy diseases modifying antirheumatic medicines |
| url | https://www.tandfonline.com/doi/10.1080/13102818.2022.2131468 |
| work_keys_str_mv | AT konstantintachkov costofarthropathicdiseasestherapywithbiologicalsdiseasemodifyingdrugsbdmarsa5yearcostanalysisatnationallevel AT vladimiraboyadzhieva costofarthropathicdiseasestherapywithbiologicalsdiseasemodifyingdrugsbdmarsa5yearcostanalysisatnationallevel AT ivanmanev costofarthropathicdiseasestherapywithbiologicalsdiseasemodifyingdrugsbdmarsa5yearcostanalysisatnationallevel AT nikolaystoilov costofarthropathicdiseasestherapywithbiologicalsdiseasemodifyingdrugsbdmarsa5yearcostanalysisatnationallevel AT zornitsamitkova costofarthropathicdiseasestherapywithbiologicalsdiseasemodifyingdrugsbdmarsa5yearcostanalysisatnationallevel AT konstantinmitov costofarthropathicdiseasestherapywithbiologicalsdiseasemodifyingdrugsbdmarsa5yearcostanalysisatnationallevel AT guenkapetrova costofarthropathicdiseasestherapywithbiologicalsdiseasemodifyingdrugsbdmarsa5yearcostanalysisatnationallevel |